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INTRODUCTION
Early screening of ﬁrst-degree relatives (FDRs) of patients with
colorectal cancer (CRC) has always been a clinical focus. However, the signiﬁcant risk to FDRs of those with advanced colorectal polyps (ACPs) and the need for earlier initiation of
screening may be overlooked. For the purposes of this manuscript, we use the term ACP to describe advanced adenomas
(AAs) (the term traditionally used in the literature) and advanced
serrated polyps.

Both CRC and ACPs diagnosed in a proband require FDRs
(parents, siblings, and children) to be screened at 40 years of age
or 10 years before the proband’s diagnosis, whichever is earlier
(1). In addition, ACPs are high-risk lesions that warrant shorter
surveillance intervals in the proband. Given the increasing incidence of early-onset CRC, it is imperative to increase awareness
of ACPs among gastroenterologists, primary care physicians, and
other providers to assure adherence to earlier screening among
FDRs.

Figure 1. National Colorectal Cancer Roundtable Advanced Colorectal Polyp GI brief. Reprinted with permission from the National Colorectal Cancer
Roundtable, American Cancer Society. GI, gastrointestinal.
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Table 1. Screening guidelines for first-degree relatives of patients with advanced adenoma

USMSTF

Diagnosis

Early screening guideline

AA or CRC in 1 FDR , 60 yr of age or 2 FDRs
(any age)

Colonoscopy every 5 yr beginning 10 yr before the age at
diagnosis or at the age of 40 yr, whichever is earlier.

AA or CRC in 1 FDR $60 yr of age

Begin screening at 40 yr of age. Options for screening and
intervals are the same as those for average-risk persons.

According to the USMSTF, when FDRs have documented advanced serrated lesions (SSPs $1 cm, SSP with cytologic dysplasia, or a TSA $ 1 cm*), there is no clear
evidence as to how to proceed (unless the relative meets criteria for serrated polyposis syndrome). They recommend screening FDRs of persons with advanced serrated
lesions similar to screening of FDRs of persons with advanced conventional adenomas (see ref. 1).
*Please note a TSA of any size is considered advanced for the proband surveillance (see ref. 11).
AA, advanced adenoma; CRC, colorectal cancer; FDR, first-degree relative; SSP, sessile serrated polyp; TSA, traditional serrated adenoma; USMSTF, United Society Multi-Society Task Force.

Herein, we provide a guide to (i) appreciate recommended
surveillance intervals for patients with ACP and early screening
for FDRs and (ii) communicate risk to patients with ACP and
their FDRs. The impetus for this guide was the development of
the Advanced Colorectal Polyp GI brief (2) (Figure 1) developed
by the American Cancer Society and the National Colorectal
Cancer Roundtable (NCCRT) Advanced Adenoma Working
Group (https://nccrt.org/resource/advanced-colorectal-polypbrief/).

screening among FDRs of patients with ACP is underutilized
and represents an area where gastroenterologists could have
a larger impact on CRC prevention.

DEFINITION AND EPIDEMIOLOGY OF ACPS
ACPs are deﬁned as any one of the following: (i) tubular adenoma $1 cm or any adenoma with villous features or highgrade dysplasia regardless of the size, (ii) sessile serrated
polyp (SSP) $1 cm or SSP with cytologic dysplasia, or (iii)
traditional serrated adenoma of any size. ACPs are the immediate precursors of CRC (3) and critical target lesions for
screening.
During screening colonoscopy, approximately 10% of
average-risk individuals are diagnosed with an AA (4). AA
prevalence is higher among men (5) but appears similar among
blacks and whites (6). The prevalence of any SSP ranges from 2
to 9% among average-risk adults undergoing screening, with
approximately half $1 cm (7) and ,1% showing cytologic
dysplasia (8). Traditional serrated adenomas are more rare
(prevalence 0.1–2.3%) (9).
PRACTICE ADVICE FOR THE ENDOSCOPIST
Step 1. Define the patient at risk

Knowing a patient’s risk is essential to providing recommendations that can be lifesaving. Individuals with AAs have
a 15.9%–19.3% risk of metachronous AA and 0.8%–1.3% risk
of metachronous CRC (10). The recommended surveillance interval for ACPs is 3 years, with earlier follow-up for piecemeal or
incompletely resected lesions (11).
FDRs of patients with AA carry a 1.68–3.90-fold increased
risk of developing CRC and 6.05-fold increased odds of developing AAs compared with those without a family history
(12,13). FDRs of patients with advanced serrated lesions may
be at a similarly increased risk, but additional data are needed
(1). The United Society Multi-Society Task Force recommends that FDRs of patients with AAs or advanced serrated
lesions initiate screening at age 40 years or 10 years before the
patient’s diagnosis, whichever is earlier (1) (Table 1). Early
The American Journal of GASTROENTEROLOGY

Figure 2. Risk communication flow. *Persons with a single first-degree
relative diagnosed at $60 years with an advanced colorectal polyp can be
offered average-risk screening options at age 40 years.
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Figure 3. Template letter included in the National Colorectal Cancer Roundtable Advanced Colorectal Polyp GI brief. GI, gastrointestinal. Reprinted with
permission from the National Colorectal Cancer Roundtable, American Cancer Society.

Common clinical scenarios. Scenario #1. An asymptomatic 39year-old man is referred to gastroenterology because his father
had a 1.2-cm tubular adenoma at the age of 67 years. Recommendation: Because of a FDR with an AA, screening should
commence at 40 years of age.
Scenario #2. A 64-year-old woman has a 1.1-cm tubular
adenoma on screening colonoscopy. Recommendation: Surveillance colonoscopy in 3 years, and counsel patient that
FDRs are at increased risk and should undergo screening at 40
years of age. In this scenario, the endoscopist needs to not
only think about surveillance colonoscopy intervals in the
proband but also be mindful of the increased risk to FDRs.
Because gastroenterologists routinely make decisions about
surveillance intervals (because of high polyp prevalence),
surveillance guidelines are at the forefront of the physician’s
approach, but communicating familial risk may potentially be
overlooked. The patient should notify their children and
siblings to talk to their physician about earlier screening.
© 2020 by The American College of Gastroenterology

Step 2. Take a thorough family history to exclude
hereditary syndromes

Documenting the family history of CRC, colorectal polyps, and
other malignancies in all patients is essential to identifying those
with underlying hereditary cancer syndromes, including Lynch
syndrome and others.
Furthermore, in the setting of multiple adenomas (lifetime
cumulative adenomas and on a single colonoscopy), polyposis syndromes need to be considered. Patients with hereditary syndromes fall outside the average-risk screening
guidelines. This also has implications for family members.
The following strategies for collecting family history can be
used, even in busy endoscopy units: (i) in advance of the visit,
provide patients with family history worksheets, (ii) use
a clinical prediction algorithm (i.e., PREMM 5 Model)
to quantify the likelihood of a Lynch syndrome gene mutation (https://premm.dfci.harvard.edu), and (iii) refer to
the NCCRT Risk Assessment and Screening Toolkit to Detect
The American Journal of GASTROENTEROLOGY
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Familial, Hereditary, and Early Onset Colorectal Cancer
(https://nccrt.org/resource/risk-assessment-and-screeningtoolkit-to-detect-familial-hereditary-and-early-onset-colorectalcancer/)
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Step 3. Communicate risk to your patient and their FDRs

CONFLICTS OF INTEREST

Postpolypectomy risk communication is critical for CRC
prevention. Preliminary data show 80% of patients with adenoma are unaware that they may be at higher risk than the
general population, 21% do not know follow-up is needed, and
68% have inaccurate knowledge of their results (Molmenti,
unpublished data). Furthermore, multiple communication
channels exist by which patients receive colonoscopy results
and risk information with no standard of care established. A
more streamlined approach to risk communication that
begins with the patient and reaches FDRs may improve the
quality of care we provide (Figure 2). It is recommended that
all such communications be documented clearly in the medical record.
The use of a computer-based bedside educational tool, administered before discharge from endoscopy units in combination with personalized letters sent through mail, is eﬀective at
improving the patient’s knowledge of results and risk perception
(for themselves and their relatives) and increases the likelihood
that patients contact their relatives, compared with standard of
care (14). Template letters developed by the NCCRT (2) can be
downloaded online, tailored to your patient, and embedded as
macros into electronic health record systems (https://nccrt.org/
wp-content/uploads/GI-Brief_ADVANCED-POLYPS-Colonoscopy-Report-Letter_ﬁnal.pdf) (Figure 3).
Another approach can be used at the time of endoscopy. If an
adenomatous or sessile serrated appearing polyp $1 cm is found,
a preliminary discussion regarding potential earlier screening of
FDRs before discharge can be carried out (and documented in the
colonoscopy report and discharge materials as there are often
recall issues because of sedation or issues related to patient loss to
follow up). A caveat is that occasionally, histology will reveal
a nonprecancerous polyp (i.e., inﬂammatory polyp). Although
this method can be useful as an adjunct, it should not serve as
a replacement for direct conﬁrmatory communication with
patients once pathology results return.

FUTURE DIRECTIONS/SUMMARY
There has always been a focus on the risk to relatives after
a proband’s CRC diagnosis, yet the United Society Multi-Society
Task Force early screening guidelines for FDRs of patients with
ACPs may be underappreciated. Improved strategies to communicate risk for colorectal neoplasia among probands and FDRs
are imperative. Furthermore, there is a need to create a culture of
awareness of ACPs among gastroenterologists, primary care
physicians, and others, whereby patients are routinely asked not
only about their family history of CRC but also about their family
history of ACPs. By increasing the dialogue regarding these advanced lesions, we can continue to make meaningful progress
toward reducing the overall burden of CRC, including early-onset
disease.
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